Riviere J E, Williams P L, Hillman R S, Mishky L M
Cutaneous Pharmacology and Toxicology Center, North Carolina State University, Raleigh 27606.
J Pharm Sci. 1992 Jun;81(6):504-7. doi: 10.1002/jps.2600810605.
The use of the isolated perfused porcine skin flap (IPPSF), an alternative in vitro animal model, to predict the profile of the concentration of arbutamine in plasma samples from humans after transdermal iontophoretic administration of this novel catecholamine is described. The strategy involved administering the drug in the IPPSF (n = 8) and assaying concentrations of drug in the venous efflux versus time (IPPSF venous efflux profile). Intravenous infusion (n = 7) and transdermal studies (n = 32) were also conducted in humans. The IPPSF profile was then used as an input into an intravenous pharmacokinetic model obtained from the human experiments to predict the profile of concentration of drug in plasma versus time (plasma concentration-time profile) seen after iontophoretic administration. The IPPSF profiles were denormalized according to the parameters used in the human studies (i.e., multiplied by in vivo concentration, electrode area, current, and dosing time). For two different sets of iontophoretic dosing conditions, the concentration-time profiles that were predicted on the basis of the IPPSF study were compared with those seen after delivery to humans.
本文描述了使用离体灌注猪皮瓣(IPPSF)这一替代性体外动物模型,来预测新型儿茶酚胺药物经皮离子导入给药后人体血浆样本中阿巴胺浓度分布情况。该策略包括在IPPSF中给药(n = 8),并测定静脉流出液中药物浓度随时间的变化(IPPSF静脉流出液浓度分布)。还在人体中进行了静脉输注(n = 7)和经皮研究(n = 32)。然后将IPPSF浓度分布作为输入,输入到从人体实验获得的静脉药代动力学模型中,以预测离子导入给药后血浆中药物浓度随时间的变化情况(血浆浓度-时间分布)。根据人体研究中使用的参数对IPPSF浓度分布进行归一化处理(即乘以体内浓度、电极面积、电流和给药时间)。对于两组不同的离子导入给药条件,将基于IPPSF研究预测的浓度-时间分布与给药给人体后观察到的浓度-时间分布进行比较。